| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514263340 | Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.) | 69 |
| 20080221133 | Compounds - The present invention relates to a compound according to Formula (I) | 09-11-2008 |
| 20080221134 | 8-ALKYNYLXANTHINES AND DERIVATIVES - Disclosed are novel compounds of the general formula (Ia), and pharmaceutically acceptable salts, isomers, diastereomers or enantiomers thereof | 09-11-2008 |
| 20080242684 | METHODS OF ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS - Provided herein are improved methods of treating subjects with adenosine A | 10-02-2008 |
| 20080275068 | Method of Using Vasoconstrictive Agents During Energy-Based Tissue Therapy - A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy. | 11-06-2008 |
| 20080293748 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors - There is disclosed the use of a compound of formula (Ia) or (Ib) | 11-27-2008 |
| 20090023755 | USE OF ISTRADEFYLLINE FOR TREATING BEHAVIORAL DISORDERS - The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like. | 01-22-2009 |
| 20090131459 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors - The present invention relates to a compound according to Formula (I) wherein R | 05-21-2009 |
| 20090197900 | METHODS OF TREATING HEART FAILURE AND RENAL DYSFUNCTION IN INDIVIDUALS WITH AN ADENOSINE A1 RECEPTOR ANTAGONIST - Provided herein are methods of improving, maintaining and restoring renal function, treating heart failure, treating subjects with acute fluid overload, and slowing or reversing an existing or developing renal impairment in subjects with BNP levels of at least 400 pg/mL and/or NT-proBNP levels of at least about 1500 pg/mL by administering a therapeutically effective amount of an AA | 08-06-2009 |
| 20090325984 | USE OF 1,7-DIMETHYLXANTHINE FOR THE MANUFACTURE OF A NON-ANXIOGENIC PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER - The present invention relates to the use of paraxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder. | 12-31-2009 |
| 20100010021 | NOVEL COMPOUNDS - The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): | 01-14-2010 |
| 20100022563 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration. | 01-28-2010 |
| 20100087455 | SUBSTITUTED XANTHINE COMPOUNDS - The present invention relates to new substituted xanthine-based agents, pharmaceutical compositions thereof, and methods of use thereof. | 04-08-2010 |
| 20100099690 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS - The present invention relates to compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial. | 04-22-2010 |
| 20100160354 | NOVEL COMPOUNDS - The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): | 06-24-2010 |
| 20100168140 | Easily Absorbable Oral Preparations of Xanthine Derivatives - An object of the present invention is to provide an easily absorbable oral preparation containing a xanthine derivative or a pharmaceutically acceptable salt thereof and a fatty acid or a fatty acid derivative for the purpose of providing an easily absorbable oral preparation containing the xanthine derivative of which absorbability has been enhanced by dissolving the xanthine derivative that shows adenosine A | 07-01-2010 |
| 20100227875 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions. | 09-09-2010 |
| 20100331349 | Use of gamma-aminobutyric acid to mask or reduce an unpleasant flavour impression and preparations containing gamma-aminobutyric - The use of γ-aminobutyric acid or a physiologically acceptable salt of γ-aminobutyric acid to mask or reduce the unpleasant flavour impression of an unpleasantly tasting substance is described. The food, beverage or oral care preparations or oral pharmaceutical preparations comprising at least one unpleasantly tasting substance and γ-aminobutyric acid are also described. | 12-30-2010 |
| 20110003834 | PRODUCTION METHOD AND PRODUCTION APPARATUS FOR A HIGH THEOBROMINE-CONTAINING COMPOSITION - An object is to provide a method for producing a high theobromine-containing composition effectively in a simple way. The method for producing a theobromine-containing composition comprises: (a) performing an extraction of a theobromine-containing plant or a processed product thereof with a solvent, to obtain a crude theobromine extract; (b) applying the crude theobromine extract to a cation exchange resin subjected in advance to hydrogen ion substitution, to allow an adsorption of theobromine onto the cation exchange resin; and (c) passing a solvent containing no ionic substance through the cation exchange resin subsequently to the step (b), to obtain a theobromine eluate. | 01-06-2011 |
| 20110039869 | COMPOSITION FOR INHIBITING THE ACTIVITY OF INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR SUBTYPE III - An agent for inhibiting the activity of inositol-1,4,5-triphospate receptor subtype 3 (IP3R3), containing caffeine and/or its analogs, and/or their pharmaceutically acceptable salts, as an active ingredient, is provided. A composition for preventing and/or treating a disease associated with Ca2+ release through IP3R3, containing the IP3R3 inhibiting agent, is also provided. | 02-17-2011 |
| 20110166166 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - Methods and compositions are provided for detection of biological substances in nasal specimen. | 07-07-2011 |
| 20110172253 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES - The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation. | 07-14-2011 |
| 20110251218 | NOVEL COMPOUNDS - The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A) or a pharmaceutically acceptable salt thereof: | 10-13-2011 |
| 20120004248 | METHODS OF USING A METHYLXANTHINE COMPOUND - The invention relates to compositions and methods for treating various diseases or medical conditions by administering a methylxanthine compound. Specifically, the invention relates to compositions and methods for treating cytochrome oxidase (CcOX) mediated diseases or medical conditions by administering compositions comprising a methyl xanthine compound. | 01-05-2012 |
| 20120010226 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin - The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects. | 01-12-2012 |
| 20120022085 | PROCESS FOR OBTAINING EXTRACTS CONTAINING METHYLXANTHINE DERIVATIVES FROM CAKES OF PLANTS OF THE GENUS THEOBROMA, AS WELL AS COMPOSITION AND USE OF SAID EXTRACT - The present invention refers to a process for obtaining standardized extracts of methylxanthine derivatives from cakes of plants of the genus | 01-26-2012 |
| 20120115891 | METHOD FOR THE INDUCTION OF A REWARD RESPONSE BY MODULATION OF DOPAMINERGIC SYSTEMS IN THE CENTRAL NERVOUS SYSTEM - A method of modulating the dopaminergic system of the central nervous system comprising administering to a subject a dopamine precursor and/or a dopamine agonist in an amount effective to induce a reward response in the subject is described, as are related compositions. | 05-10-2012 |
| 20120122897 | METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS - Methods of treating movement disorders by administering an effective amount of one or more adenosine A | 05-17-2012 |
| 20120149719 | BITTER TASTE MASKING DOSAGE FORM - A powder-particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder-particle dosage form could mask bitter taste of a drug. | 06-14-2012 |
| 20120157478 | Hair Care Compositions and Methods to Improve Hair Appearance - Hair care compositions and methods that can increase the appearance of healthier hair by increasing the appearance of thicker and fuller hair, longer hair, and/or delayed emergence of gray hair. Such compositions can be applied to any areas where healthier hair appearance is desired, such as the scalp or face. | 06-21-2012 |
| 20120178768 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration. | 07-12-2012 |
| 20120184570 | Theophylline Derivative Inhibits Osteoporosis - The theophylline derivative disclosed in the present invention is characterized by having the pharmaceutical functions of osteoporosis. The theophylline derivative protects against bone resorption and inflammatory mediator infiltration. | 07-19-2012 |
| 20120208832 | PROCESS FOR CONVERTING A SOLID (METH)ACRYLATE COPOLYMER INTO A DISPERSED FORM BY MEANS OF A DISPERSING AGENT - The present invention provides a process for converting a solid (meth)acrylate copolymer into a dispersed form by preparing an aqueous dispersion comprising the components (a) a (meth)acrylate copolymer which is composed of free-radical polymerized methyl methacrylate, ethylacrylate and a salt of 2-trimethylammoniumethyl methacrylate, present in solid form as a powder or as a granulate, (b) up to 50% by weight calculated on the (meth)acrylate copolymer (a) of a dispersing agent selected from the groups of (b) i) plasticizers in combination with emulsifiers and/or (b) ii) pharmaceutically acceptable carbohydrates having 6 to 18 carbon atoms with a functional group and (c) water by mixing the components (a), (b) and (c) to give a suspension which becomes an aqueous dispersion during the conversion of the solid (meth)acrylate copolymer into the dispersed form, characterized in that, the (meth)acrylate copolymer is converted into the dispersed form by means of the presence of the dispersing agent at a temperature of less than 50° C. | 08-16-2012 |
| 20130137710 | CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS - The present invention relates to the cosmetic, dermatological or therapeutic use of certain cyclohexyl carbamate compounds of formula (I) given below, preferably as anti-cellulite actives. The invention further relates to compositions and cosmetic, dermatological or therapeutic products comprising such compounds of formula (I), which are preferably suitable for the prophylaxis (prevention) and cosmetic treatment (combating) of cellulite in human beings, corresponding methods and novel compounds of formula (I) | 05-30-2013 |
| 20130143903 | REMEDY FOR MIGRAINE HEADACHE - A medicated formulation and method of use for treating migraine having a combination of active ingredients including: nicotine, and tryptophan alone and also with phenylalanine and/or, tyrosine, and/or caffeine in an aqueous solution. | 06-06-2013 |
| 20130143904 | COMPOSITION FOR INHIBITING THE ACTIVITY OF INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR SUBTYPE III - An agent for inhibiting the activity of inositol-1,4,5-triphospate receptor subtype 3 (IP | 06-06-2013 |
| 20130150383 | NOVEL COMPOUNDS - The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): | 06-13-2013 |
| 20130150384 | METHOD FOR TREATMENT OF BRAIN CANCERS - A method for preventing and/or treating brain tumor, including administering caffeine and/or its analog, and/or their pharmaceutically acceptable salt, as an active ingredient, to a patient in need thereof, is provided. The method for preventing or treating brain tumor has an activity to inhibit invasion, migration, and proliferation of brain tumor cells, and thereby very effective for the prevention and treatment of brain tumor. | 06-13-2013 |
| 20130210840 | Anti-Cellulite Composition and Method of Treating Cellulite - A cellulite-reducing topical composition comprising a lecithin organogel, an ethylene oxide-propylene oxide-ethylene oxide triblock copolymer, caffeine, a retinoid, and optionally at least one vitamin, vitamin derivative or vitamin precursor. | 08-15-2013 |
| 20130261136 | COFFEE EXTRACTS AS INGREDIENTS OF FOODS, DRUGS, COSMETICS, DIETARY SUPPLEMENTS, AND BIOLOGICS - Embodiments are related to compositions of matter comprising a food, drug, cosmetic, dietary supplement, or biologic product, said product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10. In related embodiments, said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process. In other related embodiments, said compositions of matter are useful for facilitating neuroprotection, inhibiting COX-2 or stimulating glucose uptake. | 10-03-2013 |
| 20130289055 | COMPRESSIBLE, HIGHLY VISCOUS POLYSACCHARIDE AND POLYOL POWDER - A powder of cold-soluble polysaccharide and polyol, which is highly viscous in water and suitable for direct compression, and a method for preparing the powder and uses thereof are described, the powder being notably intended for preparing solid forms with controlled release of an active principle. | 10-31-2013 |
| 20140073654 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. | 03-13-2014 |
| 20140073655 | METHOD FOR TREATING FATIGUE - The present invention refers to an active moiety of | 03-13-2014 |
| 20140080847 | Compositions and Methods for Affecting Energy Balance, Body Composition, Fitness, and Well-Being - The invention discloses compositions, including nutritional products and dietary supplements, comprising 1,4-dimethylpentylamine, which is a compound that occurs naturally in the geranium plant. The invention also describes methods comprising the administration of 1,4-dimethylpentylamine to mammals. The methods result in stimulation of the central nervous system, improved mood, increased vigor, increased lipolysis, increased energy expenditure, enhanced exercise performance, and/or decreased appetite. These effects influence energy balance and can promote weight loss, improve body composition, and/or promote fitness and well-being. | 03-20-2014 |
| 20140128415 | EXCIPIENT DRUG COMPOSITION - A excipient drug composition is disclosed. The excipient drug composition may include a vegetable cellulose or a fruit cellulose, an active ingredient and a genetically modified organism free starch. The vegetable cellulose or fruit cellulose may be derived from wood free vegetable pulp and the fruit cellulose is a wood pulp free cellulose. The genetically modified organism free starch may be selected from the group consisting of a genetically modified organism free rice starch, a genetically modified organism free potato starch or a genetically modified organism free pea starch. | 05-08-2014 |
| 20140194447 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Compounds and their pharmaceutically acceptable salts for treatment of β-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease. | 07-10-2014 |
| 20140206704 | STARCH-BASED MICROPARTICLES FOR THE RELEASE OF AGENTS DISPOSED THEREIN - The invention provides starch-based microparticles with high loading capacity for the stabilization and/or controlled release of one or more agents, for example, a pharmaceutical, a taste masking agent, a flavoring agent, or a combination thereof, disposed within the microparticles, and to methods of making and using such microparticles. | 07-24-2014 |
| 20140235656 | SUBLINGUAL PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIHISTAMINE AGENT AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof. | 08-21-2014 |
| 20140249166 | METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS - The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A | 09-04-2014 |
| 20140256749 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS - One aspect of the invention relates to caffeine-containing compositions comprising caffeine and one or more esters. The caffeine-containing compositions disclosed herein can be used for effective transdermal delivery of caffeine to a subject. Another aspect of the invention relates to applications and preparations of the caffeine-containing compositions. | 09-11-2014 |
| 20140256750 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 09-11-2014 |
| 20140256751 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 09-11-2014 |
| 20140256752 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 09-11-2014 |
| 20140323505 | ORAL RINSE COMPOSITION AND METHOD TO DELIVER ENERGY SUPPLEMENTS - An oral rinse composition that comprises an aqueous solution that includes a high molecular weight polymer and an energy supplement that stimulates central nervous system activity. | 10-30-2014 |
| 20140343081 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING ALKYL POLYPENTOSIDE VESICLES, AND METHOD FOR PREPARING THE SAME - The present invention relates to a cosmetic or dermatological composition containing a continuous aqueous phase in which are dispersed vesicles based on at least one alkyl polypentoside, and also comprising at least one alcohol and at least one surfactant. | 11-20-2014 |
| 20150018375 | COMPOSITIONS, METHOD, AND KITS FOR TREATING PULMONARY CONDITIONS - Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and/or a leucine metabolite, and resveratrol. | 01-15-2015 |
| 20150119407 | SUBSTITUTED XANTHINE DERIVATIVES - This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial. | 04-30-2015 |
| 20150119408 | Process For The Production Of An Enriched Natural Antioxidant Mixture From A Single Source Plant - A process for extracting antioxidants from a plant, including contacting a plant material from a guayusa plant for a first time with a solvent, thereby obtaining a first slurry, filtering said first slurry, thereby obtaining a first extract, contacting said plant material for a second time with said solvent, thereby obtaining a second slurry, filtering said second slurry, thereby obtaining a second extract, combining said first extract and said second extract, thereby generating an third extract containing at least antioxidants, xanthines, and amino acids, and substantially drying said third extract. | 04-30-2015 |
| 20150141441 | AUGMENTED COGNITIVE TRAINING - The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents. | 05-21-2015 |
| 20150359771 | TREATING PULMONARY CONDITIONS - Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and/or a leucine metabolite, and resveratrol. | 12-17-2015 |
| 20150359895 | COPROCESSED SILICA COATED POLYMER COMPOSITION - The present invention provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises vinyl lactam derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared by a continuous process and has a Brookfield cohesion of less than 0.12 kPa, a bulk density of at least 0.249 gram/milliliter and a flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold. | 12-17-2015 |
| 20150366247 | METHOD AND SYSTEM FOR MODIFYING RAW FOODS, AND RAW FOOD PRODUCT MADE THEREBY - A method for modifying a quality of a fruit includes cutting a live stem attached to a live fruit at a cut distance from the fruit, producing a cut end of the stem, contacting only the cut end of the stem with a solution comprising at least one mobile and quality-modifying food ingredient while protecting the fruit from contact with the solution, and keeping the cut end of the stem in contact with the solution for an incubation time sufficient to allow absorption and transport of the food ingredient into the fruit, the food ingredient conferring a modified quality upon the fruit. A system for practicing the method and an edible raw plant product produced by the method are also disclosed. | 12-24-2015 |
| 20150366810 | SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE - It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release matrix preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release matrix preparation comprising (A) a pharmacologically active drug, (B) a combination of cellulose derivatives, and (C) mannitol. | 12-24-2015 |
| 20150366869 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. | 12-24-2015 |
| 20150366870 | NOVEL COMPOUNDS - The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A): | 12-24-2015 |
| 20160045459 | Pharmaceutical Combination - A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 02-18-2016 |
| 20160050965 | PRE-OPERATIVE CARBOHYDRATE-RICH BEVERAGE COMPOSITION AND METHODS OF TREATMENT - Provided herein are beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation comprising: a) one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage; b) an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage; c) a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor; d) a sweetener and e) water, wherein the beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting. Further provided herein are methods of using the pre-operative beverage compositions disclosed herein in preparation for the safe induction of anesthesia or sedation in a patient before surgery. | 02-25-2016 |
| 20160101107 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 04-14-2016 |
| 20160120989 | COPROCESSED SILICA COATED POLYMER COMPOSITION - An excipient composition having good bulk density and improved flow characteristics is provided. The present invention particularly provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises cellulose derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared in a continuous process and has excellent compactability and improved flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold, is characterized by a Brookfield cohesion factor of less than 0.2 kPa and a bulk density of at least 0.249 g/ml. | 05-05-2016 |
| 20160184204 | FORMULATIONS CONTAINING SPHINGANINE - The present invention relates to formulations comprising
| 06-30-2016 |
